, Déclaration de liens d'intérêts : DC déclare des liens d'intérêts potentiels : Board VIH France de Gilead jusqu'en 2015, consultant pour Innavirvax et Merck Switzerland, contrats de Janssen, MSD et ViiV, présentations pour Janssen et MSD. JPS déclare des liens d'intérêts potentiels : consultant ou adboard pour Gilead
Prise en charge médicale des personnes vivant avec le VIH, Recommandations du groupe d'experts. Rapport, 2017. ,
Causes of death among HIV-infected patients in France in 2010 (national survey): trends since, AIDS, vol.28, issue.8, pp.1181-91, 2000. ,
, Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies, Lancet, vol.372, issue.9635, pp.293-302, 2008.
Expanded European AIDS case definition, Lancet, vol.341, issue.8842, p.441, 1993. ,
The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study, Int J Cancer, vol.129, issue.2, pp.467-75, 2011. ,
Cancer-related causes of death among HIVinfected patients in France in 2010: evolution since, PloS One, vol.10, issue.6, p.129550, 2000. ,
URL : https://hal.archives-ouvertes.fr/hal-01289134
Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study, Lancet HIV, vol.2, issue.7, pp.288-98, 2015. ,
Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study, Lancet HIV, vol.4, issue.11, pp.495-504, 2017. ,
Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort, AIDS, vol.28, issue.14, pp.2109-2127, 2014. ,
Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV, J Clin Oncol, vol.30, issue.35, pp.4360-4366, 2012. ,
Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study, Lancet Oncol, vol.10, issue.12, pp.1152-1161, 2009. ,
Chapter 6: immunosuppression and co-infection with HIV, J Natl Cancer Inst Monogr, issue.31, pp.41-47, 2003. ,
Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis, Lancet, vol.370, issue.9581, pp.59-67, 2007. ,
HIV infection, immunodeficiency, viral replication, and the risk of cancer, Cancer Epidemiol Biomarkers Prev, vol.20, issue.12, pp.2551-2560, 2011. ,
Elevated incidence of lung cancer among HIV-infected individuals, J Clin Oncol, vol.24, issue.9, pp.1383-1391, 2006. ,
Risk of cancer among HIV-infected individuals compared to the background population: impact of smoking and HIV, AIDS, vol.28, issue.10, pp.1499-508, 2014. ,
Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer, J Natl Cancer Inst, vol.103, issue.14, pp.1112-1134, 2011. ,
Tobacco smoking increases immune activation and impairs T-cell function in HIV infected patients on antiretrovirals: a cross-sectional pilot study, PloS One, vol.9, issue.5, p.97698, 2014. ,
Autoimmune diseases in HIV-infected patients: 52 cases and literature review, Autoimmun Rev, vol.13, issue.8, pp.850-857, 2014. ,
Biological follow-up of patients with HIV treated with anti-PD-1 or anti-PD-L1 for non-small cell bronchial carcinoma ,
, Rev Mal Respir, vol.33, issue.6, pp.419-440, 2016.
Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients, AIDS, vol.20, issue.2, pp.1-7, 2006. ,
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper, Ann Oncol, vol.27, issue.4, pp.559-74, 2016. ,
Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.28, issue.4, pp.119-161, 2017. ,
Programmed death-1 expression on CD4+ and CD8+ T cells in treated and untreated HIV disease, AIDS, vol.28, issue.12, pp.1749-58, 2014. ,
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression, Nature, vol.443, issue.7109, pp.350-354, 2006. ,
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction, Nat Med, vol.12, issue.10, pp.1198-202, 2006. ,
Enhancing SIV-specific immunity in vivo by PD-1 blockade, Nature, vol.458, issue.7235, pp.206-216, 2009. ,
Effect of ipilimumab on the HIV reservoir in an HIVinfected individual with metastatic melanoma, AIDS, vol.29, issue.4, pp.504-510, 2015. ,
Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer ,
URL : https://hal.archives-ouvertes.fr/hal-02163559
, Ann Oncol, 2017.
Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy, J Infect Dis, vol.215, issue.11, pp.1725-1758, 2017. ,